Featured Clinical Trials Supported by the National Cancer Institute
Today, thousands of cancer clinical trials are under way in the United States. Clinical trials answer vital research questions that lead to better screening, prevention, diagnosis, and treatment options for all cancers. This section highlights NCI-supported cancer trials and demonstrates the breadth of clinical cancer research supported by the Institute.
To find other cancer trials open to enrollment:
- Call NCI's Cancer Information Service at 1-800-4-CANCER (1-800-422-6237) for information about trials all across the country. The call is toll-free and completely confidential.
- Use the clinical trials search form to look online for trials listed on NCI's Cancer.gov Web site. The form has a Help link for tips about searching for clinical trials.
- For information about cancer trials taking place on the National Institutes of Health campus in Bethesda, Maryland, call NCI’s Clinical Trials Referral Office at 1-888-NCI-1937 (1-888-624-1937). The call is toll-free and completely confidential.
(Posted: 09/25/2007, Updated: 03/16/2010) - In this clinical trial, researchers are exploring the potential of pomegranate juice to slow or reverse increasing PSA levels in men who have undergone treatment for localized prostate cancer.
Extending Targeted Immune Depletion to Unrelated Cord Blood Transplantation
(Posted: 03/09/2010) - In this pilot study, patients with leukemia, lymphoma, multiple myeloma, or certain premalignant blood disorders (such as myelodysplastic syndromes) will undergo targeted immune-depleting chemotherapy followed by unrelated double cord blood transplant.
Treating Pain from Chemotherapy-Induced Peripheral Neuropathy
(Posted: 02/23/2010) - In this trial, patients with painful peripheral neuropathy caused by prior treatment with paclitaxel or oxaliplatin will be randomly assigned to receive either duloxetine or placebo pills for 6 weeks.
Sorafenib for Metastatic Prostate Cancer
(Posted: 01/23/2007, Updated: 02/09/2010) - In this clinical trial, patients with metastatic, androgen-independent prostate cancer will be treated with sorafenib, a small-molecule inhibitor that blocks the activity of several cancer-related proteins.
Optimizing Chemotherapy with Bevacizumab for Ovarian Cancer
(Posted: 02/09/2010) - In this trial, patients with stage II-IV ovarian epithelial, fallopian tube, or primary peritoneal cancer will be randomly assigned to receive one of three regimens using intravenous or intravenous and intraperitoneal chemotherapy in addition to bevacizumab.